Alprostadil combined with Irbesartan in treatment of early diabetic nephropathy
10.3760/cma.j.issn.1008-6315.2011.09.022
- VernacularTitle:前列地尔联合厄贝沙坦治疗早期糖尿病肾病效果观察
- Author:
Zifen SUN
;
Xizhi XING
;
Pengxia LI
;
Yubin LIU
;
Jinpeng LIU
;
Yanmin WANG
- Publication Type:Journal Article
- Keywords:
Diabetic nephropathy;
Alprostadil;
Irbesartan;
24 hour urine albumin
- From:
Clinical Medicine of China
2011;27(9):956-958
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical efficacy of combined irbesartan and alprostadil treatment of early diabetic nephropathy (DN).Methods A total of 120 patients with early type 2 diabetes of hospitalization were randomly divided into 3 groups: irbesartan group of 40 patients (150 mg, once per day)(group irbesartan),40 patients treated with alprostadil (physiological saline and alprostadi 10 μg))(group alprostadi) ,40 patients treated with alprostadil combined irbesartan (dose same as the other two groups)(combined group).All cases were observed for 4 weeks.Comparison of serum creatinine (Cr), blood urea nitrogen(BUN) ,24 hour urinary albumin(24hUAE) changes after treatment.ResultsAfter treatment 4 weeks 24hUAE of the three groups were significantly decreased (t = 2.07, t = 2.01 and t = 3.15, Ps ＜ 0.05) .The decrease of 24hUAE in the combined treatment group ([252.69 ± 33.56]mg/24h) was better than that in the irbesartan group([268.75 ± 34.42)](t = 2.11, P ＜ 0.05)and in the alprostadil group ([267.95 ± 30.75])mg/24h (t = 1.998, P ＜ 0.05) .No significant difference were observed between the Irbesartan and alprostadil group.During treatment, several patients affected by swell, uncomfortable in the alprostadil group, but improved after treatment.No other adverse effect was observed.Conclusion Alprostadil combined with irbesartan treatment of early diabetic nephropathy is an effective way.
